Paper Details

  1. Home
  2. Paper Details

Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds.

Author: AbagyanRuben, DebnathAnjan, EhrenkauferGretchen, SauveyConall, ShiDa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Several FDA-approved antineoplastic kinase inhibitors were found to be potent amoebicidal agents against Entamoeba histolytica, including dasatinib, bosutinib, ibrutinib, ponatinib, neratinib, and olmutinib. Ibrutinib showed both amoebicidal and cysticidal properties, offering a potential alternative to current therapeutic strategies.
Paper Details　
Original Abstract of the Article :
Entamoeba histolytica is a protozoan parasite which infects approximately 50 million people worldwide, resulting in an estimated 70,000 deaths every year. Since the 1960s E. histolytica infection has been successfully treated with metronidazole. However, drawbacks to metronidazole therapy exist, inc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895358/

データ提供：米国国立医学図書館（NLM）

Fighting Amoebiasis with Antineoplastic Kinase Inhibitors

The world of [parasitic infections] is a fascinating and often challenging field. This study explores the potential of [antineoplastic kinase inhibitors] as a novel therapeutic approach for [Entamoeba histolytica infection]. The authors performed in vitro studies to evaluate the efficacy of these inhibitors against amoebic trophozoites. Their findings revealed that [certain antineoplastic kinase inhibitors] exhibited potent amoebicidal activity, offering a promising alternative to existing treatments. The study also highlights the potential of [ibrutinib] as a promising candidate for treating amoebiasis due to its [amoebicidal and cysticidal properties].

New Hope for Treating Amoebiasis

This research provides evidence for the potential of [antineoplastic kinase inhibitors] to be effective in treating [amoebiasis]. The identified inhibitors displayed [amoebicidal activity] at relatively low concentrations, suggesting their potential as [novel therapeutic agents]. The study also emphasizes the importance of [further research and clinical trials] to evaluate the safety and efficacy of these inhibitors in human patients.

A Promising Path to Combatting Amoebiasis

This exciting research offers a glimmer of hope for combating [amoebiasis]. The study’s findings highlight the potential of [antineoplastic kinase inhibitors] to be effective in tackling this widespread and devastating disease. As we learn more about these inhibitors, we may be able to develop new and effective treatments, ultimately bringing us closer to conquering this challenging parasitic infection.

Dr.Camel's Conclusion

Like the camel navigating the vast and unforgiving desert, this study explores a new path in the battle against amoebiasis. Antineoplastic kinase inhibitors hold the potential to transform treatment strategies, bringing us closer to a brighter future for those affected by this debilitating disease.

Date :
  1. Date Completed 2021-06-08
  2. Date Revised 2022-02-25
Further Info :

Pubmed ID

33556060

DOI: Digital Object Identifier

PMC7895358

Related Literature

Article Analysis
・Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.